Will it be possible to slow the rate of human aging and extend lifespan? Maybe. Assuming that the first metazoans had short lifespans, gene changes have already extended our lifespans dramatically. Species with tissues much like ours can live far longer than we do, suggesting that perhaps we could too. In some human families, living healthily to age ninety or older is commonplace. With more knowledge of the genes responsible, it might be possible to design interventions to slow down aging and increase healthy lifespan.
In animals, many mutations can slow aging and extend lifespan, in some cases dramatically. Most of these life-extending mutations affect biochemical pathways that respond to nutrient, stress or energy levels. Inhibiting pathways that promote nutrient uptake or growth, or activating pathways that normally help the organism respond to stress or a shortage of energy, can extend lifespan in worms, flies and mice. Perhaps pharmaceutical techniques could be used to extend human lifespans by modifying these or other life-extension pathways.
Now, writing in eLife, Yuan Zhang of the University of Texas Southwestern (UTSW) Medical Center and co-workers report that a hormone, called fibroblast growth factor-21 (FGF-21), can extend lifespan in mice (Zhang et al., 2012). When food is withheld from an animal for 12 hours or longer, liver cells produce this hormone, which then mobilizes fat stores in the liver, and promotes the synthesis of glucose and ketones. FGF-21 also reduces basal insulin levels and increases insulin sensitivity. In addition, it suppresses further growth of the mice by preventing growth hormone from triggering the production of IGF-1 (insulin-like growth factor-1) in the liver.
Previously, a collaboration between the UTSW group and researchers at New York University School of Medicine engineered mice with levels of circulating FGF-21 that were 5–10 times higher than normal (Inagaki et al., 2008). As a consequence, these animals switched on their starvation response even though they continued to feed normally. Now Zhang et al. report that the median lifespans of these mice are increased—by 30% for male mice and 39% for female mice. One consequence of high levels of FGF-21, disruption of the growth hormone/insulin/IGF-1 pathway, is already known to extend the lifespan of mice by ∼50% (Coschigano et al., 2000). This disruption is likely to be responsible for the increase in the lifespans observed by Zhang et al. Other life extension pathways they examined (the TOR, AMPK and sirtuin pathways) all appeared normal in these mice.
Because FGF-21 is a hormone, it should be possible to increase its level in humans. It is possible that this will extend lifespan, because there are already hints that inhibiting the growth hormone/IGF-1 pathway promotes human longevity. First, genetic mutations that prevent cells from responding to IGF-1 are over-represented in centenarians (Suh et al., 2008), as are other rare DNA variants that reduce the activities of other components of this pathway, including the receptor for growth hormone (Y. Suh, personal communication). Second, DNA variants in the FOXO3A gene have been linked to exceptional longevity in at least eight studies across the world. FOXO proteins switch on genes that extend lifespan when insulin/IGF-1 signalling is inhibited in animals, although we do not know how these human DNA variants affect gene function. Third, genome-wide association studies for longevity highlight this pathway (Deelen et al., 2011).
It was the ability of FGF-21 to help animals survive starvation that initially prompted Zhang and co-workers – who are based at UTSW, the Howard Hughes Medical Institute and the Salk Institute – to test its role in aging. It has been known for decades that a reduced calorie intake (caloric restriction) can increase the lifespans of rodents and other animals. When first discovered, during the Great Depression of the 1930s, caloric restriction was assumed to work simply by reducing metabolic wear and tear. However, now we know that it extends lifespan by engaging specific signalling pathways and changing patterns of gene expression.
The results of a long-running caloric restriction experiment on primates were published recently and, unexpectedly, it was found that the calorically restricted monkeys did not live any longer than control animals (Mattison et al., 2012). This finding was puzzling because caloric restriction had seemed to extend lifespan in a previous study (Colman et al., 2009). However, the monkeys in the previous study had consumed a high-glycemic-index diet, and the control animals (the only group in either study with a relatively short lifespan) were allowed to eat all they wanted. The take-home message here might be that a healthy, moderate diet will provide just as much benefit as more severe food limitation. However, the differences between the outcomes of the two studies might be partly due to other factors, such as genotypic differences between the groups. Different strains of mice are now known to respond to caloric restriction in different ways: some strains even live shorter, not longer.
While caloric restriction is not fully understood, Zhang et al. show that it is unlikely to explain their results because caloric restriction does not trigger FGF-21 production. Intriguingly, however, recurrent periods of starvation, administered in the form of intermittent, every-other-day feeding, can also extend lifespan in animals. This regime does not reduce overall caloric intake, as the animals overeat when food is available, but it should trigger FGF-21 production. Moreover, in C. elegans, where the mechanism has been examined, the life extension produced by intermittent fasting appears to act by inhibiting insulin/IGF-1 signalling and activating FOXO (Honjoh et al., 2009). It would be interesting to know whether every-other-day feeding might extend the lifespans of primates.
One of the most exciting features of many long-lived worms, flies and mice is their resistance to age-related diseases such as cancer, atherosclerosis and protein-aggregation disease. Since FGF-21 activates the same longevity pathways, it is possible that this hormone might also confer resistance against disease. Unfortunately, like some other mice that are deficient in IGF-1, these long-lived mice have low bone density, so we cannot recommend injecting FGF-21 right now.
Caloric restriction delays disease onset and mortality in rhesus monkeysScience 325:201–204.
Assessment of growth parameters and life span of GHR/BP gene-disrupted miceEndocrinology 141:2608–2613.
Gene set analysis of GWAS data for human longevity highlights the relevance of the insulin/IGF-1 signaling and telomere maintenance pathwaysAge (Dordr), 10.1007/s11357-011-9340-3.
Signalling through RHEB-1 mediates intermittent fasting-induced longevity in C. elegansNature 457:726–730.
Inhibition of growth hormone signaling by the fasting-induced hormone FGF21Cell Metab 8:77–83.
Impact of caloric restriction on health and survival in rhesus monkeys from the NIA studyNature 489:318–321.
Functionally significant insulin-like growth factor I receptor mutations in centenariansProc Natl Acad Sci USA 105:3438–3442.
The starvation hormone, fibroblast growth factor-21, extends lifespan in miceeLife 1:e00065.
One-dimensional (1D) target search is a well-characterized phenomenon for many DNA-binding proteins but is poorly understood for chromatin remodelers. Herein, we characterize the 1D scanning properties of SWR1, a conserved yeast chromatin remodeler that performs histone exchange on +1 nucleosomes adjacent to a nucleosome-depleted region (NDR) at gene promoters. We demonstrate that SWR1 has a kinetic binding preference for DNA of NDR length as opposed to gene-body linker length DNA. Using single and dual color single-particle tracking on DNA stretched with optical tweezers, we directly observe SWR1 diffusion on DNA. We found that various factors impact SWR1 scanning, including ATP which promotes diffusion through nucleotide binding rather than ATP hydrolysis. A DNA-binding subunit, Swc2, plays an important role in the overall diffusive behavior of the complex, as the subunit in isolation retains similar, although faster, scanning properties as the whole remodeler. ATP-bound SWR1 slides until it encounters a protein roadblock, of which we tested dCas9 and nucleosomes. The median diffusion coefficient, 0.024 μm2/s, in the regime of helical sliding, would mediate rapid encounter of NDR-flanking nucleosomes at length scales found in cellular chromatin.
The transformation of normal to malignant cells is accompanied by substantial changes in gene expression programs through diverse mechanisms. Here, we examined the changes in the landscape of transcription start sites and alternative promoter (AP) usage and their impact on the translatome in TCL1-driven chronic lymphocytic leukemia (CLL). Our findings revealed a marked elevation of APs in CLL B cells from Eµ-Tcl1 transgenic mice, which are particularly enriched with intra-genic promoters that generate N-terminally truncated or modified proteins. Intra-genic promoter activation is mediated by (1) loss of function of ‘closed chromatin’ epigenetic regulators due to the generation of inactive N-terminally modified isoforms or reduced expression; (2) upregulation of transcription factors, including c-Myc, targeting the intra-genic promoters and their associated enhancers. Exogenous expression of Tcl1 in MEFs is sufficient to induce intra-genic promoters of epigenetic regulators and promote c-Myc expression. We further found a dramatic translation downregulation of transcripts bearing CNY cap-proximal trinucleotides, reminiscent of cells undergoing metabolic stress. These findings uncovered the role of Tcl1 oncogenic function in altering promoter usage and mRNA translation in leukemogenesis.